ION Exchange (India) Limited — Investor Meet, 21-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Ion Exchange (India) Limited reported consolidated operating income of INR 6,445 million for the quarter, up 21% year-on-year. EBITDA increased by 13% to INR 682 million with a margin of 10.58%. Net profit also grew by 19% to INR 506 million, with a PAT margin of 7.85%. For the first half of FY25, operating income reached INR 12,120 million, reflecting 20% growth, while net profit soared by 26% to INR 954 million. The Engineering Division stood out with a 26% revenue increase to INR 3,949 million due to improved execution of large EPC contracts.

2. **Future Outlook and Growth Drivers**: Management emphasized a sustained focus on leveraging the robust domestic enquiry pipeline and expanding market presence. The upcoming commercial production from the expanded Roha plant in FY26 is expected to bolster the Chemicals Division, alongside efforts in the consumer products segment to address negative margins through increased market penetration.

3. **Order Book and Operational Updates**: The Engineering Division's order book is healthy at INR 3,580 crores, supported by ongoing project execution. The company secured an order inflow of INR 726 crores in H1, with a strong Q2 performance of INR 578 crores, indicating an encouraging trend.

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts inquired about future profitability, with management confident in maintaining margins at last year’s levels, despite challenges from specific contracts.

- **Market Position and Competitive Landscape**: Discussions highlighted competitive dynamics within the sector, with management confident in their unique project mix to drive sustained growth.

- **Operational Challenges or Risks**: Management acknowledged challenges related to execution speed, particularly in UP, where approvals and fund disbursements have been slow but improving.

- **Capex and Capital Allocation**: Analysts probed current and future capital expenditures related to new facilities. Management provided clarity on CAPEX for the Roha plant, estimating significant turnover from the investment.

- **Strategic Priorities and Long-Term Vision**: The focus remains on expanding into international markets and high-growth sectors like biotechnology and semiconductors, aligning with long-term strategic goals.

5. **Market or Regulatory Updates**: The company is witnessing improvements in fund allocation from government projects, particularly post-election, which had previously stalled execution rates.

6. **Strategic Focus Areas**: Innovation and gradually capturing international market share are key themes, alongside addressing operational efficiencies to enhance profitability.

7. **Investor Insight**: Ion Exchange demonstrates strong revenue growth and operational momentum, suggesting positive sentiment. Given the financial health and growth potential, a ‘buy’ position appears warranted, especially considering the promising outlook for the engineering and chemicals segments.